Research programme: inflammation therapy - LION bioscience/Ono

Drug Profile

Research programme: inflammation therapy - LION bioscience/Ono

Alternative Names: IL-10 synthesis inhibitors - LION bioscience/Ono; Interleukin-10 synthesis inhibitors - LION bioscience/Ono

Latest Information Update: 01 Dec 2003

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Ono Pharmaceutical; SYGNIS Pharma
  • Class
  • Mechanism of Action Interleukin 10 modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Inflammation

Most Recent Events

  • 31 Dec 2002 Discontinued - Preclinical for Inflammation in USA (unspecified route)
  • 11 Apr 2001 Trega Biosciences has been acquired by LION bioscience
  • 18 Apr 2000 Preclinical development for Inflammation in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top